Dr. Hooman Kamel

 A multi-center, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to results reported by researchers at Weill Cornell Medicine, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

A new onset of a rapid or irregular heartbeat that develops after surgery, often within a few days, is associated with an increased risk for hospitalization for heart failure among patients undergoing both cardiac and noncardiac surgery, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

People who have experienced a cerebral hemorrhage or brain bleed have a two-fold increase in the risk of having an ischemic stroke (caused by an artery blockage) or heart attack, compared with members of the general population.

The short-term risk of a second stroke following an initial minor stroke is roughly 60 percent higher for black patients compared with white patients, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian researchers.

As brain disorders such as Alzheimer’s disease, autism and depression increase in frequency, the synergistic fields of neurology and psychiatry may illuminate important clues that can lead to innovative treatments for these conditions.

Young people with a history of strokes caused by blood clots should be evaluated for a congenital condition characterized by a hole in the heart. If present, surgical closure should be considered to prevent future stroke, according to an editorial by a Weill Cornell Medicine and NewYork-Presbyterian neurologist.

ARCADIA, a multicenter phase III trial, will study the role of abnormalities in the structure and function of the heart’s left atrium, or atrial cardiopathy, in stroke patients, and test a medication that could prevent them from experiencing recurrent strokes.

With a state-of-the-art mobile unit and pioneering research, Weill Cornell Medicine is at the vanguard of treating stroke patients — for whom ‘time is brain’